Meeting
2023 ASCO Gastrointestinal Cancers Symposium
FGFR2-amplified gastroesophageal adenocarcinoma is a distinct genomic class: Lessons learned from a liquid biopsy platform.
Authors
Bushra Shariff
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
Bushra Shariff , Reagan Barnett , Farshid Dayyani , Steven Brad Maron , Samuel J Klempner , Jude Masannat , Leylah Drusbosky , Rory Mcgriskin , Rutika Mehta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 429)
DOI
10.1200/JCO.2023.41.4_suppl.429
Abstract #
429
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA-based genomic landscape of early-onset pancreatic cancer.
First Author: Reagan Barnett
Poster
2019 Gastrointestinal Cancers Symposium
FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.
First Author: Samuel Jacob Klempner
Poster
2017 Gastrointestinal Cancers Symposium
Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.
First Author: Steven Brad Maron